How should Zoladex (goserelin) be discontinued safely, including necessary hormonal coverage and monitoring?

Zoladex Withdrawal: Discontinuation Protocol

Simply stop Zoladex injections without tapering—the medication is reversible and will naturally wear off over time, with ovarian function typically recovering within 12 weeks in women and testosterone levels normalizing within several months in men. 1

Discontinuation Method

• No special tapering protocol is required—just discontinue scheduled injections. 1
• The biodegradable depot formulation will continue releasing goserelin until the polymer matrix is exhausted, then effects gradually reverse. 2
• For the 3.6 mg monthly depot, suppression persists for approximately 4 weeks after the last injection; for the 10.8 mg quarterly depot, effects may persist for up to 12 weeks. 2

Hormonal Recovery Timeline

In Women (Breast Cancer or Benign Conditions)

• Expect delayed return of menses—ovarian function recovery is variable but typically occurs within 12 weeks after discontinuation. 1
• Effective nonhormonal contraception must continue for 12 weeks following discontinuation if pregnancy prevention is desired, as ovarian function may recover unpredictably. 1
• Warning: Some patients may experience persistent amenorrhea even after discontinuation—this is rare but documented. 1
• Monitor for physiologic signs of ovarian function recovery: resumption of menses and/or cyclical fluctuations in menopausal symptoms (hot flashes becoming intermittent rather than constant). 3

In Men (Prostate Cancer)

• Testosterone levels will rise after discontinuation—research shows testosterone can reach normal levels within 100-160 days after stopping goserelin. 4
• In prostate cancer patients, PSA levels typically increase as testosterone recovers, indicating return of androgen-dependent tumor activity. 4
• If disease progression occurs during Zoladex therapy and you're considering switching to surgical castration, maintain awareness that testosterone suppression by GnRH agonists is not permanent—bilateral orchiectomy may still provide benefit even after Zoladex failure. 4

Monitoring After Discontinuation

For Women

• Monitor for return of menses as the primary indicator of ovarian function recovery. 1
• If patient was on Zoladex for breast cancer with concurrent tamoxifen or aromatase inhibitor therapy, continue the oral endocrine therapy as prescribed—the ASCO guideline recommends 5 years of ovarian suppression when indicated, so premature discontinuation should be discussed carefully. 3
• Do not routinely measure estradiol levels—clinical signs (menses, vasomotor symptoms) are sufficient. 3
• Bone density monitoring: If patient received prolonged Zoladex therapy (especially >6 months), consider baseline DEXA scan after discontinuation, as bone loss occurs during treatment but typically recovers after cessation in most patients. 1

For Men

• In prostate cancer patients, monitor PSA and testosterone levels if clinically indicated (e.g., if considering alternative hormonal therapy). 4
• Testosterone recovery can be documented by serum testosterone measurements at 3-6 month intervals if needed for clinical decision-making. 4

Hormonal Coverage During Withdrawal

No bridging hormonal therapy is required during Zoladex withdrawal—the medication's effects persist during the washout period. 1

Exception for Breast Cancer Patients

• If discontinuing Zoladex in a premenopausal woman with hormone receptor-positive breast cancer who was on combination therapy (Zoladex + tamoxifen or AI), continue the oral endocrine agent (tamoxifen or switch to tamoxifen if on AI, since AIs require postmenopausal status). 3
• The ASCO guideline emphasizes that ovarian suppression should be continued for 5 years when indicated for high-risk patients—early discontinuation due to intolerable symptoms is acceptable, but this represents a deviation from optimal therapy. 3

Managing Withdrawal Symptoms

Symptom Rebound

• Hot flashes and other menopausal symptoms will gradually resolve as estrogen levels recover in women. 1
• Some patients may experience temporary worsening of vasomotor symptoms during the transition period as hormone levels fluctuate. 3
• Depression may persist or worsen during withdrawal—maintain vigilance for mood changes and provide appropriate psychiatric support if needed. 1

Bone Health

• Bone mineral density typically recovers after cessation in women, though recovery may be incomplete in patients with additional risk factors (chronic corticosteroid use, smoking, alcohol abuse, family history of osteoporosis). 1
• In men, consider bisphosphonate therapy if prolonged GnRH agonist use has occurred, as bone loss may not fully reverse. 1

Special Considerations

When Discontinuation is Appropriate

• Intolerable, untreatable symptoms (severe vasomotor symptoms, depression, sexual dysfunction) that dramatically impair quality of life. 3
• Disease progression in cancer patients, necessitating change in therapy. 4
• Completion of planned treatment duration (5 years for breast cancer with ovarian suppression; ongoing for metastatic prostate cancer until progression). 3, 1

When to Reconsider Discontinuation

• In breast cancer patients at high risk of recurrence, the benefits of continued ovarian suppression may outweigh quality of life concerns—have thorough risk-benefit discussions before stopping. 3
• If patient has not completed the recommended 5-year duration for breast cancer, premature discontinuation increases recurrence risk. 3